Search results for "Drug Incompatibility"

showing 5 items of 5 documents

Interactions of α-tocopherol with biomembrane models: Binding to dry lecithin reversed micelles

2005

Abstract The state of α-tocopherol (Vitamin E) in solutions of dry lecithin reversed micelles dispersed in an apolar medium has been investigated as a function of the Vitamin E to surfactant molar ratio (RVE) at fixed surfactant concentration by FT-IR, 1H NMR and SAXS with the aim to emphasize the role played by anisotropic intermolecular interactions and confinement effects as driving forces of its partitioning between apolar bulk solvent and polar nanodomains and of mutual Vitamin E/reversed micelle effects. It has been found that its binding strength to reversed micelles, triggered by steric and orientational constrains, is mainly regulated by specific interactions between the hydrophili…

Magnetic Resonance Spectroscopyfood.ingredientreversed micelleChemistry Pharmaceuticalmedicine.medical_treatmentPharmaceutical Sciencevitamin EMicelleLecithinDrug IncompatibilitySurface-Active Agentschemistry.chemical_compoundfoodPulmonary surfactantalpha-tocopherolPhosphatidylcholineSpectroscopy Fourier Transform InfraredmedicineOrganic chemistryTocopherolCarbon TetrachlorideMicellesVitamin EBiological membraneVitaminsintermolecular interactionlecithinchemistryPhosphatidylcholinesBiophysicslipids (amino acids peptides and proteins)solubilization.alpha-TocopherolInternational Journal of Pharmaceutics
researchProduct

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

2010

Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the over…

Malemedicine.medical_specialtyMeasles-Mumps-Rubella VaccineInfluenza vaccineAntibodies ViralVaccines AttenuatedRubellaMeaslesDrug IncompatibilityPlacebosRubella vaccineInternal medicineInfluenza HumanmedicineLive attenuated influenza vaccineHumansVaccines CombinedMumpsAdministration IntranasalRubellaGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessMeasles-Mumps-Rubella Vaccinemedicine.drugMeaslesVaccine
researchProduct

Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions

2008

Patients suffering from cystic fibrosis (CF) often need to inhale multiple doses of different nebulizable drugs per day. Patients attempt to shorten the time consuming administration procedure by mixing drug solutions/suspensions for simultaneous inhalation. The objective of this experimental study was to determine whether mixtures of the nebulizer solution dornase alfa (Pulmozyme) with tobramycin nebulizer solutions (TOBI and GERNEBCIN 80 mg) are physico-chemically compatible. Drug combinations were prepared by mixing the content of one respule Pulmozyme with either one respule TOBI or one ampoule GERNEBCIN 80 mg. Test solutions were stored at room temperature and exposed to light. Dornase…

Pulmonary and Respiratory MedicineChemical PhenomenaCystic FibrosisExcipientAmpouleDrug Incompatibilitychemistry.chemical_compoundAdministration InhalationTobramycinDeoxyribonuclease IHumansMedicinePotencyChromatographyInhalationbusiness.industryNebulizers and VaporizersDornase alfaSodium metabisulfiteAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionsNebulizerchemistryAnesthesiaPediatrics Perinatology and Child HealthTobramycinbusinessmedicine.drugPediatric Pulmonology
researchProduct

Development and characterization of co-loaded curcumin/triazole-halloysite systems and evaluation of their potential anticancer activity.

2014

Abstract Positively charged halloysite nanotubes functionalized with triazolium salts (f-HNT) were employed as a carrier for curcumin molecules delivery. The synthesis of these f-HNT new materials is described. Their interaction with curcumin was evaluated by means dynamic light scattering (DLS) and UV–vis spectroscopy in comparison with pristine unmodified HNT (p-HNT). The curcumin load into HNT was estimated by thermogravimetric analysis (TGA) measurements, while the morphology was investigated by scanning electron microscopy (SEM) techniques. Release of curcumin from f-HNT, at three different pH values, by means of UV–vis spectroscopy was also studied. Furthermore, different cancer cell …

Thermogravimetric analysisCurcuminCell SurvivalScanning electron microscopeTriazolePharmaceutical ScienceAntineoplastic Agentsengineering.materialHalloysiteSettore MED/13 - EndocrinologiaDrug Incompatibilitychemistry.chemical_compoundhalloysite nanotubes triazolium salts drug carrier curcumin in vitro anticancer activityDynamic light scatteringCell Line TumorHumansTechnology PharmaceuticalOrganic chemistrySolubilityCell ProliferationSettore CHIM/02 - Chimica FisicaDrug CarriersNanotubesSettore CHIM/06 - Chimica OrganicaTriazolesDrug LiberationchemistryThermogravimetryMicroscopy Electron ScanningengineeringCurcuminClayAluminum SilicatesDrug carrierNuclear chemistry
researchProduct

Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.

2012

The objective of this in-vitro study was to determine whether admixtures of the inhalation solutions Pulmozyme(®) (Dornase alfa) and either Bramitob(®) or Tobi(®) (both containing Tobramycin) are physicochemically compatible and to analyze the aerodynamic parameters of these admixtures. After mixing, test solutions were stored at room temperature and under ambient light conditions over a period of 24 h. Tobramycin concentrations were determined by using a fluorescence immunoassay. Stability of dornase alfa was determined by size-exclusion high performance liquid chromatography, ultraviolet spectroscopy, sodium dodecyl sulfate polyacrylamide gel electrophoresis and tentacle strong cation-exc…

Pulmonary and Respiratory MedicineTime FactorsDrug StorageHigh-performance liquid chromatographyDrug Incompatibilitychemistry.chemical_compoundDrug StabilityAdministration InhalationmedicineTobramycinGeometric standard deviationDeoxyribonuclease IPharmacology (medical)Sodium dodecyl sulfateParticle SizeAerosolsChromatographyInhalationNebulizers and VaporizersBiochemistry (medical)Osmolar ConcentrationDornase alfaHydrogen-Ion ConcentrationRecombinant ProteinsAnti-Bacterial AgentsDrug CombinationsPharmaceutical SolutionschemistryCompatibility (mechanics)TobramycinFeasibility StudiesParticle fractionmedicine.drugPulmonary pharmacologytherapeutics
researchProduct